Articles From: Abiomed Receives Continuous Access Protocol (CAP) for RECOVER RIGHT Impella RP Study to Acquisition of Furiex Pharmaceuticals, Inc. by Forest Laboratories, Inc. May Not Be in Shareholders' Best Interests


DANVERS, Mass., May 21, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) , a leading provider of breakthrough heart support technologies, today announced it has received approval for implementation of a Continuous Access Protocol (CAP) from the Food & Drug Administration (FDA) for RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella® RP (Right Peripheral) System.
Sign-up for Abiomed Receives Continuous Access Protocol (CAP) for RECOVER RIGHT Impella RP Study investment picks
DANVERS, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc .
Sign-up for Abiomed's Impella(R) Technology Showcased at EuroPCR 2014 investment picks
Growth Driven by Strength in North American Education and Corporate Markets VANCOUVER , May 12, 2014 /PRNewswire/ - Absolute® Software Corporation ("Absolute" or the "Company") (TSX: ABT) , the industry standard for persistent endpoint security and management solutions for computers, laptops and ultra-portable devices and the data they contain, today announced its financial results for the three- and nine-month periods ended March 31, 2014 .
Sign-up for Absolute Software Reports Fiscal 2014 Third Quarter Results investment picks
2014/5/5
Absolute Software to Host Conference Call for Fiscal 2014 Third Quarter Financial Results Canada NewsWire A press release announcing the quarterly results will be issued at 1:00 p.m. PT , ( 4:00 p.m. ET ) that same day.
Sign-up for Absolute Software to Host Conference Call for Fiscal 2014 Third Quarter Financial Results investment picks
2014/5/9
SCOTTSDALE, Ariz.
Sign-up for Abtech Holdings Invited to Present at the 2014 LDMICRO Invitational in Los Angeles investment picks
LAVAL, Quebec, May 21, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its consolidated financial results for the fourth quarter and fiscal year ended February 28, 2014.
Sign-up for Acasti Announces Fourth Quarter and Fiscal Year Results investment picks
LAVAL, Quebec, May 1, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today that it will be presenting at two upcoming scientific forums.
Sign-up for Acasti to Present at Two Scientific Forums investment picks
TUCSON, Ariz.
Sign-up for Accelerate Diagnostics Announces Final Results of Rights Offering investment picks
Founder of Boston-based Kerry Capital Advisors, Mr.
Sign-up for Accelerating Its Team-Building Momentum, Global Digital Solutions, Inc. Adds Thomas W. Janes, Leading Private Equity and Investment Banking Expert, to the Company's Advisory Board investment picks
LAKE ZURICH, Ill., April 7, 2014 (GLOBE NEWSWIRE) -- ACCO Brands Corporation (NYSE:ACCO) will release first quarter 2014 financial results at approximately 7:00 a.m. Eastern Time on Wednesday, April 30, 2014.
Sign-up for ACCO Brands to Webcast First Quarter Earnings Call Wednesday, April 30, 2014 investment picks
SAN DIEGO, April 21, 2014 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today announced the appointment of Paul Smith to its senior management team in the newly created position of Vice President, International.
Sign-up for Accomplished International Ophthalmic Industry Executive Joins TearLab investment picks
2014/5/7
Accord Reports Record Funds Employed And Record First Quarter Factoring Volume And Announces First Quarter 2014 Earnings Canada NewsWire The Company's financial statements have been prepared in accordance with IFRS.
Sign-up for Accord Reports Record Funds Employed And Record First Quarter Factoring Volume And Announces First Quarter 2014 Earnings investment picks
SUNNYVALE, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY) , announced today that its management is scheduled to present at the 2014 Jefferies Global Healthcare Conference in New York City on Tuesday, June 3, 2014 at 3 p.m. ET/ 12 p.m. PT.
Sign-up for Accuray Incorporated to Present at 2014 Jefferies Global Healthcare Conference investment picks
Achieves Positive Cash Flow on Strong Revenue Growth SUNNYVALE, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY) announced today financial results for the third fiscal quarter and nine months ended March 31, 2014.
Sign-up for Accuray Reports Financial Results for Third Quarter of Fiscal Year 2014 investment picks
SUNNYVALE, Calif., April 10, 2014 (GLOBE NEWSWIRE) -- Accuray Incorporated (Nasdaq:ARAY) announced today that it will report results for its third quarter of fiscal 2014, ended March 31, 2014 on Wednesday, April 30, 2014 after the market closes.
Sign-up for Accuray to Report Financial Results for Third Quarter Fiscal 2014 investment picks
2014/5/1
http://media.marketwire.com/attachments/201404/74764_acelogo.jpg http://media.marketwire.com/attachments/201404/74763_valspar.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1111433&ProfileId=051205&sourceType=1 OAK BROOK, IL --
Sign-up for Ace Hardware and Valspar Paint Unveil Revolutionary New Paint Department With "Helpful Is Beautiful" Campaign investment picks
PORT WASHINGTON, N.Y., May 8, 2014 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Board of Directors has declared a regular quarterly dividend of $0.06 per common share.
Sign-up for ACETO Board of Directors Declares Quarterly Cash Dividend investment picks
Combination Accelerates Business Shift to Higher Margin Finished Dosage Generics PORT WASHINGTON, N.Y., April 30, 2014 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that its wholly-owned subsidiary, Rising Pharmaceuticals ("RISING"), has closed the acquisition of 100% of the equity interests of PACK Pharmaceuticals, LLC ("PACK"), a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products.
Sign-up for ACETO Corporation Completes Acquisition of PACK Pharmaceuticals, LLC investment picks
PORT WASHINGTON, N.Y., April 25, 2014 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the third quarter of fiscal 2014 ended March 31, 2014 after the stock market close on Thursday, May 8, 2014.
Sign-up for ACETO Corporation Schedules Fiscal 2014 Third Quarter Financial Results News Release and Conference Call investment picks
PORT WASHINGTON, N.Y., May 8, 2014 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET) , a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the third quarter of fiscal 2014 ended March 31, 2014.
Sign-up for ACETO Reports Third Quarter Fiscal 2014 Financial Results investment picks
SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO) , a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter ended March 31, 2014.
Sign-up for Achaogen Announces First Quarter 2014 Results investment picks
SOUTH SAN FRANCISCO, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO) , a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 13 th Annual Needham Healthcare Conference in New York, New York.
Sign-up for Achaogen to Present at 13th Annual Needham Healthcare Conference investment picks
- Dosing Initiated in Phase 1 Study to Evaluate the Safety, Tolerability and Antiviral Activity of ACH-3422, NS5B Uridine-Analog Nucleotide Prodrug - NEW HAVEN, Conn., April 30, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that is has begun dosing study participants with ACH-3422, Achillion's proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial.
Sign-up for Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV investment picks
NEW HAVEN, Conn., May 7, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2014.
Sign-up for Achillion Reports First Quarter 2014 Financial Results investment picks
NEW HAVEN, Conn., May 1, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at three upcoming investor conferences: The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com .
Sign-up for Achillion to Present at Three Upcoming Investor Conferences investment picks
2014/5/6
http://media.marketwire.com/attachments/201302/57392_Achronixlogoresized.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1111899&ProfileId=051205&sourceType=1 SANTA CLARA, CA --
Sign-up for Achronix Announces PCI-SIG(R) Compliance for Hardened PCI Express on Speedster22i FPGAs investment picks
2014/5/15
NEW YORK (MarketWatch) -- Pershing Square Capital Management, the hedge fund run by Bill Ackman, sold the remainder of its stake in Proctor & Gamble (PG) during the previous quarter, his company's 13-F filing revealed Thursday.
Sign-up for Ackman dumps remainder of P&G stake investment picks
SHANGHAI , May 13, 2014 /PRNewswire/ -- Acorn International, Inc. (NYSE: ATV) ("Acorn" or the "Company"), a media and branding company in China engaged in developing, promoting, and selling products through extensive direct and distribution networks, will release its financial results for the first quarter 2014 before the market opens on Tuesday, May 27, 2014 .
Sign-up for Acorn International to Announce First Quarter 2014 Financial Results on May 27, 2014 investment picks
SAN DIEGO and CHARLOTTE, N.C., May 12, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Chelsea Therapeutics International, Ltd (NASDAQ: CHTP) by the private equity firm H.
Sign-up for Acquisition Chelsea Therapeutics International, Ltd by H. Lundbeck A/S May Not Be in Shareholders' Best Interests investment picks
SAN DIEGO and MORRISVILLE, N.C. , April 28, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) by Forest Laboratories, Inc. (NYSE: FRX) .
Sign-up for Acquisition of Furiex Pharmaceuticals, Inc. by Forest Laboratories, Inc. May Not Be in Shareholders' Best Interests investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Abiomed Receives Continuous Access Protocol (CAP) for RECOVER RIGHT Impella RP Study to Acquisition of Furiex Pharmaceuticals, Inc. by Forest Laboratories, Inc. May Not Be in Shareholders' Best Interests
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry